Blood concentrations and clinical effect of cyclosporin in psoriasis

Therapeutic Drug Monitoring

Volumn 18, Issue 5, 1996, Pages 544-548

  Furlanut, Mario ^a   Baraldo, Massimo ^a   Pea, Federico ^a   Marzocchi, Vanda ^b   Croattino, Luisa ^b   Galla, Francesco ^b  

^a UNIVERSITY OF UDINE   (Italy)

^b SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Blood concentrations; Cyclosporin; Psoriasis

Indexed keywords

CREATININE; CYCLOSPORIN A;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSORIASIS;

ADULT; AGED; BLOOD PRESSURE; CREATININE; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PSORIASIS; TREATMENT OUTCOME;

EID: 0029761232     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199610000-00004     Document Type: Article

References (16)

1. Mueller W, Herrman B. Cyclosporine for psoriasis. N Engl J Med 1979;301:555.
2. Lindholm A, Zachariae H, Reitamo S, et al. Is cyclosporine blood concentration monitoring necessary in patients treated for severe chronic plaque form psoriasis? Transplant Proc 1990;22:1293-5.
3. Galla F, Marzocchi V, Croattino L, Poz D, Baraldo M, Furlanut M. Oral and intravenous disposition of cyclosporin in psoriatic patients. Ther Drug Monit 1995;17:302-4.
4. Frederiksson T, Petterson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157: 238-44.
5. Wang PP, Simpson E, Meucci V, Morrison M, Lunetta S, Cyclosporine monitoring by fluorescence polarization immunoassay. Clin Biochem 1991;24:55-8.
6. Ptachcinski RJ, Venkataramanan R, Buckart GJ. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 1986; 11:107-32.
7. Rodighiero V. Therapeutic drug monitoring of cyclosporin. Clin Pharmacokinet 1989;16:27-37.
8. Mockli G, Kabra PM, Kurtz TW. Laboratory monitoring of cyclosporine levels. Guidelines for the dermatologist. J Am Acad Dermatol 1990;23:1275-9.
9. Feutren G, Miller C. Low predictive value of cyclosporine level for efficacy or renal dysfunction in psoriasis and idiopathic nephrotic syndrome. Transplant Proc 1990; 22:1299-302.
10. Timonen P, Friend D, Abeywickrama K, Laburte C, Von Graffenried B, Feutren G. Efficacy of low-dose cyclosporin A in psoriasis: results of dose-finding studies. Br J Dermatol 1990;122:33-9.
11. A consensus report: cyclosporin A therapy for psoriasis. Br J Dermatol 1990;122:1-3.
12. Feutren G, Abeywickrama K, Friend D, Von Graffenried B. Renal function and blood pressure in psoriatic patients treated with cyclosporin A. Br J Dermatol 1990;122: 57-69.
13. Brown AL, Wilkinson R, Thomas TH, et al. The effect of short-term low-dose cyclosporin on renal function and blood pressure in patients with psoriasis. Br J Dermatol 1993;128:550-5.
14. Furlanut M, Baraldo M, Pea F, Albanese MC, Albertini A, Puricelli C. Effect of fluctuations of blood cyclosporin concentrations on renal function. Transplant Proc 1994; 26:2574-5.
15. Mehring N, Neumann KH, Rahn KH, Zidek W. Mechanism of cyclosporin A induced vasoconstriction in the isolated perfused rat kidney. Nephron 1992;60:477-81.
16. Dieperink H, Lyssac PP, Starklint, Kemp E. Cyclosporine A administration: once a day or in fractional doses? Transplant Proc 1988;20:703-6.